PT725641E - Novos inibidores da fosforilase da uridina (urdpase) e da desidrogenase do di-hidrouracilo (dhudase) - Google Patents
Novos inibidores da fosforilase da uridina (urdpase) e da desidrogenase do di-hidrouracilo (dhudase) Download PDFInfo
- Publication number
- PT725641E PT725641E PT94929398T PT94929398T PT725641E PT 725641 E PT725641 E PT 725641E PT 94929398 T PT94929398 T PT 94929398T PT 94929398 T PT94929398 T PT 94929398T PT 725641 E PT725641 E PT 725641E
- Authority
- PT
- Portugal
- Prior art keywords
- phenylthio
- barbituric acid
- pyrimidine
- phenylselenenyl
- compounds
- Prior art date
Links
- 108010019092 Uridine phosphorylase Proteins 0.000 title claims abstract description 64
- 239000003112 inhibitor Substances 0.000 title claims description 55
- OIVLITBTBDPEFK-UHFFFAOYSA-N DIHYDRO-URACILE Natural products O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 title description 8
- 102000006405 Uridine phosphorylase Human genes 0.000 title description 7
- 101710088194 Dehydrogenase Proteins 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 238000011282 treatment Methods 0.000 claims abstract description 36
- -1 methoxy, benzyl Chemical group 0.000 claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000001580 bacterial effect Effects 0.000 claims abstract description 14
- 230000002538 fungal effect Effects 0.000 claims abstract description 14
- 230000003612 virological effect Effects 0.000 claims abstract description 13
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 12
- 208000031888 Mycoses Diseases 0.000 claims abstract description 12
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 12
- 208000036142 Viral infection Diseases 0.000 claims abstract description 12
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 4
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 4
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000002532 enzyme inhibitor Substances 0.000 claims description 20
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 18
- 229960002949 fluorouracil Drugs 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 14
- 231100000419 toxicity Toxicity 0.000 claims description 13
- 230000001988 toxicity Effects 0.000 claims description 13
- 229940035893 uracil Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 8
- YWWZCHLUQSHMCL-UHFFFAOYSA-N diphenyl diselenide Chemical compound C=1C=CC=CC=1[Se][Se]C1=CC=CC=C1 YWWZCHLUQSHMCL-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 6
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 6
- 229960004413 flucytosine Drugs 0.000 claims description 6
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- UTKBQCBAMCEBTL-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)-5-phenylsulfanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COCCO)C(=O)NC(=O)C1SC1=CC=CC=C1 UTKBQCBAMCEBTL-UHFFFAOYSA-N 0.000 claims description 5
- OUAPULXYUWUOHW-UHFFFAOYSA-N 1-(ethoxymethyl)-5-fluoropyrimidine-2,4-dione Chemical compound CCOCN1C=C(F)C(=O)NC1=O OUAPULXYUWUOHW-UHFFFAOYSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 5
- KFSPSGWABMNFIY-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)-5-phenylselanylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(COCCO)C=C1[Se]C1=CC=CC=C1 KFSPSGWABMNFIY-UHFFFAOYSA-N 0.000 claims description 4
- STBPEGOCUIKHIM-UHFFFAOYSA-N 5-phenylmethoxy-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1OCC1=CC=CC=C1 STBPEGOCUIKHIM-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- YWJXYUXIPSIOGG-UHFFFAOYSA-N 1-((2-hydroxyethoxy)methyl)-5-(phenylthio)pyrimidine-2,4(1h,3h)-dione Chemical compound O=C1NC(=O)N(COCCO)C=C1SC1=CC=CC=C1 YWJXYUXIPSIOGG-UHFFFAOYSA-N 0.000 claims description 3
- GQERGAYPZWJSAF-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)-5-phenylselanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COCCO)C(=O)NC(=O)C1[Se]C1=CC=CC=C1 GQERGAYPZWJSAF-UHFFFAOYSA-N 0.000 claims description 3
- JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 claims description 3
- QBEIABZPRBJOFU-CAHLUQPWSA-N 4-amino-5-fluoro-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)CC1 QBEIABZPRBJOFU-CAHLUQPWSA-N 0.000 claims description 3
- KKWYFXCDFFPFIF-UHFFFAOYSA-N 5-phenyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O=C1NC(=S)NC=C1C1=CC=CC=C1 KKWYFXCDFFPFIF-UHFFFAOYSA-N 0.000 claims description 3
- KRPWRQUISWCMBL-UHFFFAOYSA-N 5-phenylsulfanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1SC1=CC=CC=C1 KRPWRQUISWCMBL-UHFFFAOYSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- ZSNNBSPEFVIUDS-SHYZEUOFSA-N 1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 ZSNNBSPEFVIUDS-SHYZEUOFSA-N 0.000 claims description 2
- DVGDDZUHRSIGQR-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-5-phenylsulfanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C1OCC=2C=CC=CC=2)=NC=C1SC1=CC=CC=C1 DVGDDZUHRSIGQR-UHFFFAOYSA-N 0.000 claims description 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims description 2
- KFRZFMXZIDRZJI-UHFFFAOYSA-N 5-phenylselanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1[Se]C1=CC=CC=C1 KFRZFMXZIDRZJI-UHFFFAOYSA-N 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 2
- LFQULJPVXNYWAG-UHFFFAOYSA-N sodium;phenylmethanolate Chemical compound [Na]OCC1=CC=CC=C1 LFQULJPVXNYWAG-UHFFFAOYSA-N 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- ALJMTFKADFATPR-UHFFFAOYSA-N 1-(ethoxymethyl)-5-phenylselanyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COCC)C(=O)NC(=O)C1[Se]C1=CC=CC=C1 ALJMTFKADFATPR-UHFFFAOYSA-N 0.000 claims 1
- PJFNWHZWZAJIND-UHFFFAOYSA-N 1-(ethoxymethyl)-5-phenylselanylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(COCC)C=C1[Se]C1=CC=CC=C1 PJFNWHZWZAJIND-UHFFFAOYSA-N 0.000 claims 1
- PMRHGPAHIQRUBY-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-5-phenylselanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C1OCC=2C=CC=CC=2)=NC=C1[Se]C1=CC=CC=C1 PMRHGPAHIQRUBY-UHFFFAOYSA-N 0.000 claims 1
- WMZFUTOHAWIHJN-UHFFFAOYSA-N 2-bromo-4-chloropyrimidine Chemical compound ClC1=CC=NC(Br)=N1 WMZFUTOHAWIHJN-UHFFFAOYSA-N 0.000 claims 1
- TYWVHIPSNSXVJG-UHFFFAOYSA-N 5-fluoro-6-(oxolan-2-yl)-1h-pyrimidine-2,4-dione Chemical compound N1C(=O)NC(=O)C(F)=C1C1OCCC1 TYWVHIPSNSXVJG-UHFFFAOYSA-N 0.000 claims 1
- 150000005752 bromopyridines Chemical class 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 39
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 39
- 230000015556 catabolic process Effects 0.000 abstract description 21
- 102000004190 Enzymes Human genes 0.000 abstract description 19
- 108090000790 Enzymes Proteins 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 19
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 238000003384 imaging method Methods 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 102
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 51
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 51
- 229940045145 uridine Drugs 0.000 description 51
- 150000003230 pyrimidines Chemical class 0.000 description 22
- 230000036470 plasma concentration Effects 0.000 description 13
- 239000002718 pyrimidine nucleoside Substances 0.000 description 13
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002777 nucleoside Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 8
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000000973 chemotherapeutic effect Effects 0.000 description 6
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 229940000635 beta-alanine Drugs 0.000 description 5
- 238000009104 chemotherapy regimen Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- YIDGOFMCVVAHPY-UHFFFAOYSA-N 2-phenylmethoxypyrimidine Chemical class C=1C=CC=CC=1COC1=NC=CC=N1 YIDGOFMCVVAHPY-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- ISAKRJDGNUQOIC-HQMMCQRPSA-N (614C)1H-pyrimidine-2,4-dione Chemical compound N1C(=O)NC(=O)C=[14CH]1 ISAKRJDGNUQOIC-HQMMCQRPSA-N 0.000 description 2
- ADVCGXWUUOVPPB-XLPZGREQSA-N 1-[(2r,4s,5s)-4-amino-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N)C1 ADVCGXWUUOVPPB-XLPZGREQSA-N 0.000 description 2
- JVMANPYCAJCWPR-UHFFFAOYSA-N 4-bromo-2,6-bis(phenylmethoxy)pyrimidine Chemical compound N=1C(OCC=2C=CC=CC=2)=NC(Br)=CC=1OCC1=CC=CC=C1 JVMANPYCAJCWPR-UHFFFAOYSA-N 0.000 description 2
- SPJAGILXQBHHSZ-UHFFFAOYSA-N 5-benzyl-1-(2-hydroxyethoxymethyl)uracil Chemical compound O=C1NC(=O)N(COCCO)C=C1CC1=CC=CC=C1 SPJAGILXQBHHSZ-UHFFFAOYSA-N 0.000 description 2
- QMPWETJGPVPWGU-UHFFFAOYSA-N 5-bromo-2,4-bis(phenylmethoxy)pyrimidine Chemical compound N1=C(OCC=2C=CC=CC=2)C(Br)=CN=C1OCC1=CC=CC=C1 QMPWETJGPVPWGU-UHFFFAOYSA-N 0.000 description 2
- MFORXTHLVUSZNY-UHFFFAOYSA-N 5-phenylsulfanyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC=C1SC1=CC=CC=C1 MFORXTHLVUSZNY-UHFFFAOYSA-N 0.000 description 2
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010088106 Dihydrouracil Dehydrogenase (NAD+) Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001576 beta-amino acids Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000007337 electrophilic addition reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000005980 lung dysfunction Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DHALQLNIDMSKHU-REOHCLBHSA-N (2s)-2-(fluoroamino)propanoic acid Chemical compound FN[C@@H](C)C(O)=O DHALQLNIDMSKHU-REOHCLBHSA-N 0.000 description 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
- YDYOYUPJKSJCMF-UHFFFAOYSA-N 1-(2-hydroxyethoxymethyl)pyrimidine-2,4-dione Chemical compound OCCOCN1C=CC(=O)NC1=O YDYOYUPJKSJCMF-UHFFFAOYSA-N 0.000 description 1
- UNRYGRHRRHNWHF-UHFFFAOYSA-N 1-(ethoxymethyl)pyrimidine-2,4-dione Chemical compound CCOCN1C=CC(=O)NC1=O UNRYGRHRRHNWHF-UHFFFAOYSA-N 0.000 description 1
- LLEDHRMCLYPYKR-DMDPSCGWSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-phenylselanylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C([Se]C=2C=CC=CC=2)=C1 LLEDHRMCLYPYKR-DMDPSCGWSA-N 0.000 description 1
- JAHLFAWFOKQUDC-DMDPSCGWSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-phenylsulfanylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(SC=2C=CC=CC=2)=C1 JAHLFAWFOKQUDC-DMDPSCGWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ISAKRJDGNUQOIC-DOMIDYPGSA-N 1h-pyrimidine-2,4-dione Chemical compound O=C1C=CN[14C](=O)N1 ISAKRJDGNUQOIC-DOMIDYPGSA-N 0.000 description 1
- RXFGNZUKBIJUON-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-6-phenylselanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C(OCC=1C=CC=CC=1)N=1)=CC=1[Se]C1=CC=CC=C1 RXFGNZUKBIJUON-UHFFFAOYSA-N 0.000 description 1
- CAVAKZBRZJXJPP-UHFFFAOYSA-N 2,4-bis(phenylmethoxy)-6-phenylsulfanylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=C(OCC=1C=CC=CC=1)N=1)=CC=1SC1=CC=CC=C1 CAVAKZBRZJXJPP-UHFFFAOYSA-N 0.000 description 1
- PXQPEWDEAKTCGB-YZRHJBSPSA-N 2,4-dioxo-(414C)1H-pyrimidine-6-carboxylic acid Chemical compound C(C1=C[14C](=O)NC(=O)N1)(=O)O PXQPEWDEAKTCGB-YZRHJBSPSA-N 0.000 description 1
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 150000005710 5-bromopyrimidines Chemical class 0.000 description 1
- XEKNACRTWJHOCE-UHFFFAOYSA-N 6-Phenyl-2-thiouracil Chemical compound O=C1NC(S)=NC(C=2C=CC=CC=2)=C1 XEKNACRTWJHOCE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 102100024265 Beta-ureidopropionase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000004088 Hyper-beta-alaninemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- JSJWCHRYRHKBBW-UHFFFAOYSA-N N-carbamoyl-beta-alanine Chemical compound NC(=O)NCCC(O)=O JSJWCHRYRHKBBW-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940122294 Phosphorylase inhibitor Drugs 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100036286 Purine nucleoside phosphorylase Human genes 0.000 description 1
- 241000736246 Pyrola Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108010036968 beta-ureidopropionase Proteins 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 108010009099 nucleoside phosphorylase Proteins 0.000 description 1
- 108091006527 nucleoside transporters Proteins 0.000 description 1
- 102000037831 nucleoside transporters Human genes 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WJCXADMLESSGRI-UHFFFAOYSA-N phenyl selenohypochlorite Chemical compound Cl[Se]C1=CC=CC=C1 WJCXADMLESSGRI-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/146,838 US5476855A (en) | 1993-11-02 | 1993-11-02 | Enzyme inhibitors, their synthesis and methods for use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT725641E true PT725641E (pt) | 2001-05-31 |
Family
ID=22519188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT94929398T PT725641E (pt) | 1993-11-02 | 1994-09-30 | Novos inibidores da fosforilase da uridina (urdpase) e da desidrogenase do di-hidrouracilo (dhudase) |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US5476855A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0725641B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP3621102B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE198046T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU699914B2 (cg-RX-API-DMAC10.html) |
| DE (1) | DE69426423T2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2155093T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT725641E (cg-RX-API-DMAC10.html) |
| WO (1) | WO1995012400A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| EP0748316B1 (en) * | 1994-02-28 | 2002-05-08 | Sunkyong Industries Co., Ltd. | Pyrimidine acyclonucleoside derivatives |
| US5811073A (en) * | 1995-06-19 | 1998-09-22 | President And Fellows Of Harvard College | Method for radioisotopic detection and localization of inflammation in a host |
| US5719132A (en) * | 1996-06-27 | 1998-02-17 | Bristol-Myers Squibb Company | Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil |
| US6306909B1 (en) | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| US6177437B1 (en) * | 1998-09-04 | 2001-01-23 | University Of Massachusetts Medical Center | Inhibitors of Herpes Simplex virus uracil-DNA glycosylase |
| US6608197B2 (en) * | 2000-01-25 | 2003-08-19 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US7501429B2 (en) * | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| CA2448160A1 (en) * | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
| EP1655301B1 (en) * | 2003-08-04 | 2015-03-11 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| CN102441170A (zh) * | 2004-12-03 | 2012-05-09 | 阿迪赫里克斯技术公司 | 与5-fu和5-fu前药组合施用dpd抑制剂的方法 |
| US20100158966A1 (en) * | 2005-05-24 | 2010-06-24 | Ted Reid | Selenium-based biocidal formulations and methods of use thereof |
| EP1898706B1 (en) * | 2005-05-24 | 2018-04-04 | Selenium, Ltd. | Selenium-based biocidal formulations and methods of use thereof |
| US9370187B2 (en) | 2005-05-24 | 2016-06-21 | Selenium, Ltd. | Selenium-based biocidal formulations and methods of use thereof |
| US8236337B2 (en) * | 2005-05-24 | 2012-08-07 | Selenium, Ltd. | Anti-microbial orthodontic compositions and appliances and methods of production and use thereof |
| US20100158967A1 (en) * | 2005-05-24 | 2010-06-24 | Ted Reid | Selenium-based biocidal formulations and methods of use thereof |
| KR101452518B1 (ko) * | 2005-08-22 | 2014-10-21 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 |
| EP2120581A4 (en) * | 2007-02-20 | 2011-03-16 | Melior Pharmaceuticals I Inc | METHODS OF IDENTIFYING LYN KINASE ACTIVATORS |
| EP2180894A4 (en) * | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | METHOD OF ACTIVATING IRS-1 AND ACT |
| WO2009114325A2 (en) | 2008-03-03 | 2009-09-17 | Tosk, Incorporated | Methotrexate adjuvants to reduce toxicity and methods for using the same |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| EP2488182B1 (en) * | 2009-10-14 | 2017-07-19 | Elion Oncology LLC | Treating neurotoxicity associated with combinations of 5-FU or its prodrugs and DPD inhibitors |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| EP3609500B1 (en) | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
| US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
| WO2025260023A1 (en) * | 2024-06-14 | 2025-12-18 | Spiral Therapeutics, Inc. | Methods of treating otic disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3755295A (en) * | 1969-10-24 | 1973-08-28 | Syntex Corp | 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof |
| US3687931A (en) * | 1970-03-19 | 1972-08-29 | Syntex Corp | Halogenated purine and pyrimidine nucleosides and process therefor |
| JPS5738774A (en) * | 1980-08-19 | 1982-03-03 | Chugai Pharmaceut Co Ltd | Uracil derivative and its preparation |
| US4868187A (en) * | 1980-09-16 | 1989-09-19 | Syntex (U.S.A.) Inc. | Anti-viral N-substituted pyrimidines |
| US4613604A (en) * | 1985-07-31 | 1986-09-23 | Brown University Research Foundation | Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine |
| CH676712A5 (cg-RX-API-DMAC10.html) * | 1988-03-31 | 1991-02-28 | Mitsubishi Chem Ind | |
| US5077280A (en) * | 1988-04-12 | 1991-12-31 | Brown University Research Foundation | Treatment of viral infections |
| DE69126469T2 (de) * | 1990-03-29 | 1998-01-29 | Mitsubishi Chem Corp | Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten |
| US5141943A (en) * | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
| US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| KR0151811B1 (ko) * | 1993-12-21 | 1998-10-15 | 강박광 | 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법 |
-
1993
- 1993-11-02 US US08/146,838 patent/US5476855A/en not_active Ceased
-
1994
- 1994-09-30 PT PT94929398T patent/PT725641E/pt unknown
- 1994-09-30 AT AT94929398T patent/ATE198046T1/de not_active IP Right Cessation
- 1994-09-30 JP JP51321195A patent/JP3621102B2/ja not_active Expired - Fee Related
- 1994-09-30 AU AU78476/94A patent/AU699914B2/en not_active Ceased
- 1994-09-30 DE DE69426423T patent/DE69426423T2/de not_active Expired - Lifetime
- 1994-09-30 WO PCT/US1994/011173 patent/WO1995012400A1/en not_active Ceased
- 1994-09-30 ES ES94929398T patent/ES2155093T3/es not_active Expired - Lifetime
- 1994-09-30 EP EP94929398A patent/EP0725641B1/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/466,470 patent/US5721241A/en not_active Expired - Lifetime
-
1997
- 1997-12-01 US US08/980,629 patent/USRE37623E1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0725641A4 (cg-RX-API-DMAC10.html) | 1996-09-04 |
| US5476855A (en) | 1995-12-19 |
| JP3621102B2 (ja) | 2005-02-16 |
| EP0725641A1 (en) | 1996-08-14 |
| JPH09507054A (ja) | 1997-07-15 |
| AU7847694A (en) | 1995-05-23 |
| ES2155093T3 (es) | 2001-05-01 |
| WO1995012400A1 (en) | 1995-05-11 |
| EP0725641B1 (en) | 2000-12-13 |
| DE69426423T2 (de) | 2001-07-12 |
| US5721241A (en) | 1998-02-24 |
| ATE198046T1 (de) | 2000-12-15 |
| AU699914B2 (en) | 1998-12-17 |
| USRE37623E1 (en) | 2002-04-02 |
| DE69426423D1 (de) | 2001-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0725641B1 (en) | NOVEL INHIBITORS OF URIDINE PHOSPHORYLASE (UrdPase) AND DIHYDROURACIL DEHYDROGENASE (DHUDase) | |
| US5141943A (en) | 5-benzyl barbiturate derivatives | |
| US5723449A (en) | Methods and compositions for inhibiting uridine secretion | |
| AU781323B2 (en) | Anti-viral pyrimidine nucleoside analogues | |
| Naguib et al. | 5-Benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase | |
| SK119993A3 (en) | Antiviral combinations | |
| BG60914B1 (bg) | Кристални оксатиоланови производни | |
| KR19990022740A (ko) | C-4' 변형 아데노신 키나아제 억제제 | |
| Goudgaon et al. | Phenylselenenyl-and phenylthio-substituted pyrimidines as inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase | |
| SK281403B6 (sk) | N4-alkoxykarbonyl-5'-deoxy-5-fluórcytidínové deriváty, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie | |
| FI112601B (fi) | Menetelmä 5-fluoriurasiilia sisältävän farmaseuttisen yhdistelmän valmistamiseksi, jolla on parantunut stabiilisuus urasiilireduktaasia vastaan | |
| JPS6337766B2 (cg-RX-API-DMAC10.html) | ||
| US4650801A (en) | Anti-cancer compositions for delivering 5-fluorouracil | |
| CS271473B2 (en) | Method of pyrimidine's new derivatives production | |
| CA2176720C (en) | Novel enzyme inhibitors, their synthesis, and methods for use | |
| JPS6337787B2 (cg-RX-API-DMAC10.html) | ||
| JPS6223723B2 (cg-RX-API-DMAC10.html) | ||
| WO2009023495A2 (en) | Bisubstrate inhibitors of adenylosuccinate synthetase | |
| NUCLEOSIDES | 3'-Azido-3'-deoxythymidine (AZT) was first synthesized by Horwitz et al. 1 and | |
| JPS6223724B2 (cg-RX-API-DMAC10.html) |